Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy

Phase 2 Completed 27 enrolled Massachusetts General Hospital AstraZeneca · collab Brigham and Women's Hospital · collab Dana-Farber Cancer Institute · collab National Cancer Institute (NCI) · collab

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: Phase II trial to study the effectiveness of gefitinib in treating patients who have locally advanced or metastatic thyroid cancer that did not respond to iodine therapy.

Timeline

Start: 2003-03
Primary completion: 2011-03
Completion: 2011-03

Outcome

Missed primary endpoint

paper There were no objective responses among the 25 patients evaluated. PMID 17985985 ↗

paper Although gefitinib therapy did not result in any tumor responses PMID 17985985 ↗

Publications

Results Pennell NA, Daniels GH, Haddad RI, Ross DS, Evans T, Wirth LJ, Fidias PH, Temel JS, Gurubhagavatula S, Heist RS, Clark JR, Lynch TJ. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid. 2008 Mar;18(3):317-23. doi: 10.1089/thy.2007.0120.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Gefitinib	Small molecule	250 mg	Oral